This company is no longer active
Frazier Lifesciences Acquisition Past Earnings Performance
Past criteria checks 0/6
Key information
-214.9%
Earnings growth rate
n/a
EPS growth rate
| Capital Markets Industry Growth | 10.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Frazier Lifesciences Acquisition makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -4 | 5 | 0 |
| 30 Jun 22 | 0 | 3 | 3 | 0 |
| 31 Mar 22 | 0 | 3 | 1 | 0 |
| 31 Dec 21 | 0 | 4 | 1 | 0 |
Quality Earnings: FLAC is currently unprofitable.
Growing Profit Margin: FLAC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if FLAC's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare FLAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FLAC is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (15.6%).
Return on Equity
High ROE: FLAC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.